摘要
替加环素是美国惠氏制药公司研发的新一代广谱抗生素药物,替加环素是目前治疗超级细菌最新的抗生素品种。本文从原研企业惠氏制药公司的替加环素专利策略、替加环素专利申请现状角度出发,对替加环素相关技术进行了解析,为国内的制药企业制定专利战略提供参考。
Tigecycline is a new generation broad-spectrum antibiotic drug developed by Wyeth Pharmaceuticals Inc. Tigecycline is the latest antibiotic variety currently used in the treatment of superbugs. This article analyzed Tigecycline-related technology through two aspects： the original research company Wyeth pharmaceutical company ＇s strategy of Tigecycline patent application、current situation of Tigecycline patent. This will provide the sake of offering consult to the domestic pharmaceutical enterprises on patent countermeasures.
作者
周静
范鑫鑫
Zhou Jing;Fan Xinxin(Patent Examination Cooperation（Hubei）Center of the Patent Office,SIPO,Wuhan 430000,China;Patent Examination Cooperation（Beijing）Center of the Patent Office,SIPO,Beijing 100000,China)
出处
《山东化工》
CAS
2018年第9期51-52,共2页
Shandong Chemical Industry
关键词
抗生素
替加环素
专利分析
antibiotics
Tigecycline
patent countermeasure
